^
    Back
    Association details:
    Biomarker:TP53 R172H
    Cancer:Pancreatic Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    6142-Gain-of-function p53R172H mutation drives accumulation of neutrophils in the pancreatic tumor microenvironment promoting resistance to immunotherapy

    Published date:
    03/09/2022
    Excerpt:
    Depleting neutrophils in mice bearing CRISPR KrasG12D/+;Trp53R172H/+ PDEC tumors augmented sensitivity to combined CD40 immunotherapy and chemotherapy….
    Secondary therapy:
    Chemotherapy